• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent
 

Depression CRO

Transpharmation are a preclinical Depression contract research organization (CRO).

Depression CRO Findings

Transpharmation has developed a platform of sensitive and highly consistent TRD preclinical assays responsive to ketamine. The chronic social defeat (CSD) mouse model has high construct, face and predictive validity and is sensitive to the effects of ketamine, providing a potential means to investigate the basic neuropathology underlying affective illnesses such as anxiety and TRD.

Our EEG platform has demonstrated robust differences in the sleep/wake profiles of Wistar Kyoto rats, (an endogenous model of depression) versus Sprague Dawley controls, which are also normalised by ketamine treatment. Furthermore, the cognitive symptoms of depression, including working memory deficits, can also be modelled using WKY rats, with ketamine again demonstrating efficacy. Our behavioural end points can be coupled with biomarker analysis to investigate the neurobiology of the disease and facilitate decision making.


depression CROThis list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk


Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design